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Abstract
Background: The prognosis of most hepatocellular carcinoma (HCC) patients is poor due to the high metastatic
rate of the disease. Understanding the molecular mechanisms underlying HCC metastasis is extremely urgent. The
role of CD24 and NDRG2 (N-myc downstream-regulated gene 2), a candidate tumor suppressor gene, has not yet
been explored in HCC.
Methods: The mRNA and protein expression of CD24 and NDRG2 was analyzed in MHCC97H, Huh7 and L-02 cells.
Changes in cell adhesion, migration and invasion were detected by up- or down-regulating NDRG2 by adenovirus
or siRNA. The expression pattern of NDRG2 and CD24 in HCC tissues and the relationship between NDRG2 and
HCC clinical features was analyzed by immunohistochemical and western blotting analysis.
Results: NDRG2 expression was negatively correlated with malignancy in HCC. NDRG2 exerted anti-tumor activity
by regulating CD24, a molecule that mediates cell-cell interaction, tumor proliferation and adhesion. NDRG2 up-
regulation decreased CD24 expression and cell adhesion, migration and invasion. By contrast, NDRG2 down-
regulation enhanced CD24 expression and cell adhesion, migration and invasion. Immunohistochemical analysis of
50 human HCC clinical specimens showed a strong correlation between NDRG2 down-regulation and CD24
overexpression (P = 0.04). In addition, increased frequency of NDRG2 down-regulation was observed in patients
with elevated AFP serum level (P = 0.006), late TNM stage (P = 0.009), poor differentiation grade (P = 0.002), tumor
invasion (P = 0.004) and recurrence (P = 0.024).
Conclusions: Our findings indicate that NDRG2 and CD24 regulate HCC adhesion, migration and invasion. The
expression level of NDRG2 is closely related to the clinical features of HCC. Thus, NDRG2 plays an important
physiological role in HCC metastasis.
Background
Invasion and metastasis are closely linked with poor
prognosis and death in HCC. Molecules capable of
inhibiting invasion and metastasis are attractive candi-
dates for targeted therapy. NDRG2 (GenBank accession
no. AF159092), initially identified in our laboratory,
belongs to the NDRG (N-myc downstream-regulated
genes) family. Members of this gene family are
involved in cell growth, differentiation, stress and hor-
monal responses [1-3]. Recently, NDRG2 has been
reported to act as a tumor suppressor [4-6]. In clinical
specimens, HCC has low or undetectable levels of
NDRG2 compared to normal adjacent tissue. Low
expression of NDRG2 is a positive indicator of clinical
parameters relevant to metastasis. NDRG2 plays a
major role in suppressing HCC metastasis by inhibiting
extracellular matrix-based, Rho-driven tumor cell inva-
sion and migration [7,8].
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aggressive behavior of HCC are not fully understood.
Adhesion molecules involved in HCC metastasis were
screened for possible contribution to NDRG2-mediated
tumor inhibition. CD24 was identified as a key NDRG2-
regulated gene. CD24 is associated with tumor metasta-
sis [9]. Increased CD24 correlates with aggressive beha-
vior in renal cell carcinoma [10], glioma [11], non-small
cell lung cancer [12], breast cancer [13], prostate cancer
[14] and ovarian cancer [15,16]. CD24 overexpression is
significantly associated with positive nodal status,
advanced disease stages and shorter disease-free survival
time [17]. CD24 is overexpressed in aggressive HCC cell
lines and in the tumor tissues of patients with recurrent
HCC. CD24 mRNA overexpression correlates strongly
with p53 gene mutation and poor HCC differentiation
[18]. Depletion of CD24 decreases cell proliferation and
metastasis [19]. In an independent HCC microarray ana-
lysis, the prognostic power of CD24 suggested that
CD24 may be a putative biomarker for the prediction of
early recurrence [20]. Thus, CD24 is a novel molecule
involved in HCC tumorigenesis and metastasis.
In this paper, NDRG2 was identified as a regulator of
HCC adhesion, migration and invasion. Through adeno-
virus-mediated NDRG2 overexpression or siRNA-
mediated NDRG2 down-regulation in HCC cell lines
and immunohistochemistry of HCC clinical specimens,
NDRG2 was found to regulate the malignant behaviors
of HCC by altering the expression of CD24; moreover,
o u rd a t as u g g e s tt h a tN D R G 2m a yb eas u i t a b l ed i a g -
nostic marker of HCC.
Methods
Cell lines and culture
The human HCC cell lines Huh7 and MHCC97H, and
the human liver cell line L-02 were obtained from the
Chinese Academy of Sciences (Shanghai, China). Cells
were maintained in Dulbecco’s Modified Eagle’sM e d -
ium (DMEM; Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum (FBS; Sijiqing
Biological Engineering Materials Co., Hangzhou, China)
at 37°C in 95% air and 5% CO2.
Gene infection
A multiplicity of infection (MOI) of 40 was determined
experimentally for MHCC97H cells. Cells were seeded
in 6-well plates at a density of 5 × 10
5 cells/well and
incubated to reach approximately 80% confluence. After
removing the medium, adenovirus expressing NDRG2
(Ad-NDRG2) or the negative control gene Lac Z (Ad-
LacZ) was added in serum-free DMEM, incubated for 2
h, replaced with fresh DMEM supplemented with 10%
FBS and incubated for 48 h.
Gene transfection
Huh7 cells were seeded in 6-well plates at a density of 5
×1 0
5 cells/well. Cells were transfected with NDRG2
siRNA or negative control siRNA (TaKaRa) using Lipo-
fectamine 2000 (Invitrogen), according to the manufac-
turer’s protocol. NDRG2 siRNA sequences were: 5’-
GCUCUCUGGAAAUUCUGAGUUGAUA-3’ (sense)
and 5’-UUAAGAGCAUAUCUCGCCAGGAUGU-3’
(antisense). Negative control siRNA sequences were: 5’-
UUCUCCGAACGUGUCACGUTT-3’ (sense) and 5’-
ACGUGACACGUUCGGAGAATT-3’ (antisense). Cells
were exposed to siRNA in DMEM for 6 h, after which
the medium was replaced with DMEM containing 10%
FBS and the cells were incubated for 48 h.
RNA isolation and Quantitative RT-PCR
Total RNA was isolated from cells using Trizol Reagent
(Invitrogen) and quantified. cDNA was synthesized from
5 μg of RNA using AMV reverse transcriptase (Promega,
Madison, WI, USA) according to the manufacturer’s
instructions. The cDNA was used as a template for real-
time quantitative PCR using the Prism 7500 real-time
PCR instrument (Applied Biosystems Inc., Foster City,
CA, USA) and the Universal Mastermix (ABI). Primers
were designed using Primer Express Software (ABI). Pri-
mer sequences were: NDRG2, 5’-GAGATATGCTCT-
TAACCACCCG-3’ (sense) and 5’-GCTGCCCAA
TCCATCCAA -3’ (antisense), product size: 90 bp; CD24,
5’-ACCTGTTTCCATTCAACAAGAGCAC-3’ (sense)
and 5’-TCTGAGATCGCACCACTGCAC-3’ (antisense),
product size: 164 bp; b-actin, 5’-AGCGAGCATCCCC-
CAAAGTT-3’ (sense) and 5’-GGGCACGAAGGCTCAT-
CATT-3’ (antisense), product size: 285 bp. The PCR
reaction consisted of 12.5 μlo fS Y B RG r e e nP C RM a s t e r
Mix, 300 nM each of forward and reverse primers, and
1.5 μl of template cDNA in a total volume of 25 μl. The
thermal cycling conditions were as follows: initial dena-
turation step at 95°C for 30 seconds, followed by 40
cycles of 95°C for 5 seconds and 60°C for 34 seconds.
Data were normalized to b-actin which was used as a
loading control.
Western blot analysis
Cells and liver tissues (see below) were lysed in 200 μL
of buffer containing 50 mM Tris (pH 7.5), 150 mM
NaCl, 1 mM MgCl2, 0.5% NP-40, 0.1 mM phenylmethyl
sulfonylfluoride (PMSF) and protease inhibitor cocktail.
A total of 20 μg of lysate (as measured by BCA protein
assay; Pierce, Rockford, IL, USA) was loaded per lane
onto 12% SDS polyacrylamide gels for separation by
electrophoresis and transfer onto Hybond nitrocellulose
membranes (GE Healthcare, Piscataway, NJ, USA).
Following transfer, membranes were incubated with 5%
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Tween-20 for 1 h at 37°C. Primary antibody was then
added and incubated overnight at 4°C. Primary antibo-
dies were anti-NDRG2 (Abnova, Taiwan, China), anti-
CD24 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and anti-b-actin (Boster, Wuhan, China). After
washing three times with PBS, membranes were incu-
bated with a horseradish peroxidase-conjugated goat
anti-mouse IgG antibody (Sigma) for 1 h. The blots
were developed with chemiluminescence substrate solu-
tion (Pierce) and exposed to X-ray film for visualization.
Adhesion assay
Next, 24-well plates were coated with collagen I (5 μg/
cm
2). Cells exposed to adenovirus or siRNA for 48 h
were seeded at a density of 1 × 10
5/well and then incu-
bated for 80 min. Five duplicate wells were set up for
each group. At the end of the experiment, cells were
washed twice with PBS to remove non-adherent cells.
The remaining cells were counted under a microscope
in five randomly-chosen fields per cm
2 of substrate sur-
face area. Experiments were repeated three times and
data were summarized as mean ± SD.
Migration assay
Cells (1 × 10
5) exposed to adenovirus or siRNA for 48 h
were plated in 6-well plates and grown to confluence.
The monolayer was wounded by scratching with a ster-
ile pipette tip lengthwise along the chamber. After
wounding, cells were washed twice with PBS and cul-
tured at 37°C for 24 h. Images were captured immedi-
ately after cell wounding (0 h) and 24 h after cell
wounding. Wound width (μm) was measured using
OpenLab software.
Invasion assay
In vitro invasion assays were performed using 24-well
transwell units with Matrigel-coated polycarbonate fil-
ters (Corning Costar, Cambridge, MA). Cells exposed to
adenovirus or siRNA for 48 h were seeded in the upper
chamber of the transwell at 1 × 10
5 cells in 500 μlo f
serum-free medium, while the bottom chamber was
filled with 200 μl of medium containing 10% FBS; After
24 h incubation, transwells were fixed with methanol for
15 min and stained with gentian violet for 10 min. Cells
in the upper chamber were removed using a cotton
swab and cells that invaded through the Matrigel to the
other side of the filter were manually counted. Experi-
ments were performed in triplicate. Data represent the
average number of cells from three filters.
HCC clinical specimen preparation
From 2007 to 2010, 50 patients (34 men and 16 women
from 21 to 72 years of age) with primary HCC were
enrolled in this study at the Xijing Hospital of the
fourth military medical university. Tumors were resected
and primary HCC was confirmed by a pathologist. The
study was approved by the research ethics committee of
Xijing Hospital. Proteins were extracted with standard
techniques as soon as the liver samples were excised.
All patients were prospectively monitored using the a-
fetoprotein (AFP) assay. Tumor differentiation was clas-
sified according to the Edmondson grading system, with
slight modification [21,22], into two groups: well-differ-
entiated HCC (grades I and II) and poorly-differentiated
HCC (grades III and IV). NDRG2 and CD24 expression
was scored as positive if > 10% of the cells showed mod-
erate to strong staining. Expression was scored as weak
if either cytoplasmic or membranous staining was noted
in < 10% of the cells. Expression was scored as negative
if neither cytoplasmic nor membranous staining was
observed [7].
Immunohistochemical analysis
Four micrometer-thick tissue sections were subjected to
immunofluorescent staining analysis. Free-floating liver
sections were blocked with 5% normal goat serum in PBS
containing 0.3% Triton X-100 for 1 h at room tempera-
ture. The sections were then incubated with the following
primary antibodies overnight at 4°C: mouse anti-NDRG2
(1:200) or rabbit anti-CD24 (1:200). For double immuno-
fluorescent staining, two antibodies were added at the
same time. After incubation with species-specific second-
ary antibodies conjugated to Cy2 or Cy3 (1:400, Jackson
ImmunoResearch, West Grove, PA) for 3 h at room tem-
perature, the fluorescent signals were visualized using a
confocal laser microscope (Olympus, Center Valley, PA).
NDRG2+ and/or CD24+ immunoreactive areas were
obtained bilaterally from every fifth section in a random
square unit (125 × 125 μm) and the percentage of immu-
noreactive area to the total area was calculated. NDRG2/
CD24 double-labeled cells were counted manually. Cy2
and Cy3 relative fluorescent intensity was measured using
the NIH image-J software.
Statistical analyses
Statistical analyses were performed using SPSS 11.0 soft-
ware. Data were summarized as mean ± SD. The c
2 test,
one-way ANOVA and post hoc Bonferroni test were
used for comparison between groups. P < 0.05 was con-
sidered statistically significant.
Results
NDRG2 and CD24 expression in HCC and normal liver
cells
The expression of NDRG2 and CD24 was examined in
three liver cell lines. MHCC97H and Huh7 are liver
cancer cells. A preliminary experiment indicated that
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invasive (data not shown). L-02 is a normal, non-inva-
sive human liver cell line. Results showed that the
mRNA and protein expression of NDRG2 in
MHCC97H cells was lower than in Huh7 cells. L-02
cells showed the highest level of NDRG2 among the
three cell lines. CD24 expression was higher in
MHCC97H cells compared to Huh7 cells while L-02
expressed the lowest level of CD24 (Figure 1).
NDRG2 regulates CD24 expression in HCC cells
To understand the regulation of NDRG2 and CD24,
MHCC97H cells, which express a low level of NDRG2,
were transiently infected with adenoviruses expressing
NDRG2. Increased NDRG2 mRNA and protein expres-
sion was detected in these cells while expression of
CD24 mRNA and protein was suppressed (Figure 2A-
C). By contrast, transfection of NDRG2 siRNA into
NDRG2-positive Huh7 cells increased CD24 expression
(Figure 2D-F).
NDRG2 modulates the adhesion, migration and invasion
of HCC cells
The behavior of Ad-NDRG2-infected MHCC97H cells
was assessed. Restoration of NDRG2 expression signifi-
cantly inhibited cell adhesion, migration and invasion
(Figure 3); By contrast, siRNA-treated Huh7 cells
showed increased adhesion, migration and invasion
compared to control cells (Figure 4).
NDRG2 and CD24 show a different expression pattern in
HCC clinical specimens
Since CD24 appeared to be regulated by NDRG2 in
HCC cell lines, the expression of NDRG2 and CD24
was studied in HCC clinical specimens by indirect
immunofluorescence. Double NDRG2/CD24 immunos-
taining indicated that CD24 was highly expressed in
tumors compared to normal adjacent tissues. Decreased
NDRG2 expression was detected in tumors while
increased expression was detected in normal adjacent
tissues. Co-expression of NDRG2 and CD24 was
observed in the cytoplasm (Figure 5A). NDRG2 fluores-
cence intensity was significantly lower in tumors than in
normal adjacent tissues (Figure 5B). By contrast, CD24
fluorescence intensity in tumors was higher than in nor-
mal adjacent tissues (Figure 5C). To confirm these
results, proteins extracted from liver tissues were
detected by western blotting analysis. Data showed that
NDRG2 expression was decreased in tumor tissues com-
pared to normal adjacent tissues; however, CD24 was
enhanced in tumor tissues (Figure 5D).
Low NDRG2 expression correlates with high CD24
expression in HCC and with histopathological features
HCC with low NDRG2 expression was strongly asso-
ciated with CD24 overexpression in tumor tissues (P =
0.04). Low NDRG2 level was more frequent in sera with
AFP > 320 ng/ml (P = 0.006). Furthermore, a significant
negative relationship was observed between NDRG2 and
Figure 1 NDRG2 and CD24 expression in MHCC97H, Huh7 and L-02 cells. Adherent MHCC97H, Huh7 and L-02 cells were collected. RNA
and protein were extracted for the detection of NDRG2 and CD24 expression by qRT-PCR (A) and western blotting analyses (B), respectively.
Data represent three independent experiments.
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Page 4 of 9Figure 2 NDRG2 modulates CD24 expression in HCC cells. NDRG2-low HCC MHCC97H cells were infected with adenovirus expressing NDRG2 (Ad-
NDRG2) or the negative control gene Lac Z (Ad-LacZ) (A-C), while NDRG2-high HCC Huh7 cells were transfected with NDRG2 siRNA (siRNA-N2) or
negative control siRNA (siRNA-NC) using Lipofectamine 2000 (D-F). RNA and protein were extracted and subjected to qRT-PCR (A, B, D and E) and
western blotting (C and F), respectively. b-actin was used as a loading control. Data represent three independent experiments. *P < 0.05 between groups.
Figure 3 Overexpression of NDRG2 suppresses the adhesion, migration and invasion of MHCC97H cells. NDRG2-low HCC MHCC97H cells
were infected with adenovirus expressing NDRG2 (Ad-NDRG2) or the negative control gene Lac Z (Ad-LacZ). The cells were subjected to adhesion (A
and B), migration (C and D) and invasion assays (E and F), respectively. In (B), (D) and (F), the histograms represent the quantification of cells attached,
wounding remaining width and cells having invaded through Matrigel. Data represent three independent experiments. *P < 0.05 between groups.
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(P = 0.009), invasive tumor features such as tumor
recurrence (P = 0.024) and tumor invasion (P = 0.004).
NDRG2 expression did not correlate with patient age,
sex or tumor size (Table 1).
Discussion
NDRG2 antagonizes transforming growth factor-b1
(TGF-b1)-mediated tumor cell invasion by down-regulat-
ing the expression of matrix metalloproteinase 2
(MMP2), plasminogen activator inhibitor type 1 (PAI-1)
and Rho GTPase activity [7]. The role of TGF-b1i n
tumors is not fully understood. TGF-b can both posi-
tively and negatively regulate tumor development.
Although TGF-b can promote tumor invasion via
induction of epithelial to mesenchymal transition (EMT)
during the later stages of tumor progression, it is a tumor
suppressor during early tumor progression [23]. Thus,
the inhibitory role of NDRG2 in HCC may depend on
other molecules that have not been fully explored.
In the present study, the expression level of NDRG2
was shown to correlate negatively with HCC invasion
and recurrence. In addition, enhanced NDRG2 expres-
sion by adenovirus decreased the invasion of HCC cells,
while siRNA-mediated inhibition of NDRG2 expression
promoted the aggressive behavior of HCC cells. More-
over, NDRG2 suppressed HCC cell adhesion, migration
and invasion partly through inhibiting CD24 expression.
CD24 mRNA and protein were decreased when HCC
cells were infected by Ad-NDRG2. By contrast, CD24
Figure 4 Down-regulation of NDRG2 increases the adhesion, migration and invasion of Huh7 cells. NDRG2-high HCC Huh7 cells were
transfected with NDRG2 siRNA (siRNA-N2) or the negative control siRNA (siRNA-NC) using Lipofectamine 2000. The cells were subjected to
adhesion (A and B), migration (C and D) and invasion assays (E and F), respectively. In (B), (D) and (F), the histograms represent the quantification
of cells attached, wounding remaining width and cells having invaded through Matrigel. Data represent three independent experiments. *P <
0.05 between groups.
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Page 6 of 9Figure 5 Analysis of NDRG2 and CD24 expression in HCC clinical specimens. (A) Tumor tissues showed weak NDRG2 staining and strong
CD24 staining whereas normal adjacent tissues showed strong NDRG2 staining and weak CD24 staining. NDRG2 and CD24 colocalized mainly in
the cytoplasm. (B) Immunofluorescence quantification with NIH image-J software. The relative fluorescence intensity of NDRG2 and CD24 in
tumors and normal adjacent tissues is shown. (C) Representative image of NDRG2 and CD24 expression in tumor and normal adjacent tissue
detected by western blotting. *P < 0.05 between groups.
Table 1 Correlation of NDRG2 expression with HCC clinical features in 50 primary HCC specimens
Features* NDRG2 expression Negative/weak (%) P
Age(years)
≤50 n = 21 18(85.7) 0.616
> 50 n = 29 22(75.9)
Sex
Male n = 34 15(44.1) 0.981
Female n = 16 7(43.8)
Tumor size
≤5 cm n = 39 23(59.0) 0.184
>5 cm n = 11 4(36.4)
CD24
Positive n = 29 22(75.9) 0.040
Negative/weak n = 21 10(47.6)
Serum AFP level(ng/ml)
≥ 320 n = 32 25(78.1) 0.006
< 320 n = 18 7(38.9)
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with NDRG2 siRNA.
CD24 was first described as a cell surface mucin-like
adhesion molecule in hematopoiesis. It is a small heavily
glycosylated protein core and consists of 27 amino acids
that binds to cell membrane [24]. CD24 has been identi-
fied as a ligand for P-selectin, an adhesion receptor on
activated platelets and endothelial cells [25]. During
metastasis, tumor cells pass through the blood stream by
binding to platelets or to endothelial cells via the interac-
tion between CD24 and P-selectin [26]. CD24 increases
tumor cell proliferation and adhesion to fibronectin, col-
lagen I, IV and laminin through the activation of alpha3-
beta1 and alpha4beta1 integrin activity [27]. Thus, CD24
is a regulator of cell-cell and cell-matrix interactions.
CD24 is highly expressed in many human cancers
[28]. Immunohistochemical cytoplasmic CD24 staining
has a strong prognostic value. CD24 staining intensity in
gastric, breast, colon, gallbladder and ovarian cancer
correlate with lymph node metastasis [17].
To further explore the expression pattern and relation-
ship of NDRG2 and CD24 in HCC, NDRG2-specific and
CD24-specific monoclonal antibodies were used to stain
clinical specimens. NDRG2 and CD24 staining was
scored semiquantitatively. Higher scores of cytoplasmic
CD24 were observed in tumor tissues compared to nor-
mal adjacent tissues. Significantly-reduced NDRG2 cyto-
plasmic staining was detected in tumor tissues compared
to normal adjacent tissues. These results, combined with
the data from HCC cell lines, indicate that NDRG2 regu-
lates CD24 expression and may affect malignant behavior
both in vitro and in vivo. Furthermore, low NDRG2 cor-
relates strongly with high CD24 and with elevated AFP,
TNM, Edmondson stage, HCC invasion and recurrence.
Therefore, the low expression of NDRG2 and high
expression of CD24 appear to be a common event in
HCC and may serve as a prognostic biomarker for malig-
nant transformation in hepatocytes. In addition, NDRG2
may act as a tumor suppressor by regulating different
molecules, such as TGF-b1 and CD24, which might lead
to greater inhibition of HCC.
Conclusion
In conclusion, this study shows for the first time that
NDRG2 is involved in HCC metastasis through regula-
tion of CD24 expression. This observation broadens our
understanding of the molecular mechanisms of HCC
metastasis and may lead to the development of new
therapeutic approaches. Further studies are needed to
explore the pathway through which NDRG2 regulates
CD24 and affects the metastasis of HCC.
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